Description

Hexarelin

 

 

 

CAS Number	140703-51-1
Other Names	Examorelin, Examorelin [INN], EP-23905, MF-6003, UNII-09QF37C617, 09QF37C617
IUPAC Name	(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Molecular Formula	C₄₇H₅₈N₁₂O₆
Molecular Weight	887.0
Purity	≥99% Pure (LC-MS)
Liquid Availability	N/A
Powder Availability	2 milligrams (lyophilized/freeze-dried)
Storage Condition	Store cold, keep refrigerated. Do NOT freeze.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

**Important Information: Each peptide comes lyophilized/freeze-dried and must be reconstituted with Bacteriostatic Water in order to be dispensable in liquid form.

Watch How To Reconstitute Peptide Video Here

Hexarelin and Cardiac Function

Hexarelin is a synthetically developed growth hormone receptor (GHR) that is known for its ability to efficiently activate the growth hormone secretagogue receptor (GHSR) in a fashion similar to that of the naturally occurring peptide, ghrelin. However, when comparing hexarelin to ghrelin, hexarelin is the more stable and potent compound of the two.

Previous studies show that ghrelin can be administered to improve cardiovascular functioning in terms of cardiac output, ejection fraction, and exercise capacity in rats experiencing chronic heart failure. While ghrelin is successful in treating heart failure it is considered a highly unstable compound, hexarelin on the other hand has shown promise in treating cardiovascular disease on the same level as ghrelin, however, hexarelin is far more stable and much more effective.

Hexarelin and Improved Cardiac Health

In a study conducted by Mao et. Al, hexarelin was administered to various animal subjects in order to observe its effects on apoptosis, ischemia-reperfusion injury, myocardial infarction, cardiac fibrosis, and atherosclerosis.

Neonatal rats were treated with varying doses of hexarelin to examine how the peptide is capable of inhibiting apoptosis in cardiomyocytes. The results of this portion of the study found that hexarelin treatment decreased levels of apoptosis induced by angiotensin II as well as doxorubicin-induced apoptosis. Additionally, it helped to increase the viability of the myocytes and promoted the survival of cardiomyocytes and cardiac epithelial cells.

Zucker rats were treated with 1 micromol/L of hexarelin and then subjected to ischemia for 30 minutes and reperfused for 120 minutes. It was found that with this dose of hexarelin for 30 days the heart damage caused by the ischemia was significantly decreased. The hexarelin treatment promoted cell survival, decreased apoptosis of the cardiomyocytes, and preserved the electrical properties of the myocytes. Furthermore, results showed that in rats treated with hexarelin there was improvement in left ventricle pressure as well as more protection against ischemia and angiotensin II secretion.

Male rats underwent ligation of the coronary artery. Four weeks after the procedure the rats were treated with 100 micrograms/kg/day of hexarelin for two weeks. The results of this portion of the study were very straightforward, it was found that this method of treatment led to a decrease in peripheral resistance, and increases in stroke volume, cardiac output, and cardiac index.

Cardiac fibrosis occurs when there is too much collagen, types I and II, and proteins being deposited throughout the cardiac muscle. Treatment with hexarelin in hypertensive rats over 5 weeks led to a decrease in cardiac fibrosis via a decrease in collagen deposition, and hydroxyproline content in the myocytes. Furthermore, hexarelin treatment decreased blood pressure, left ventricular hypertrophy, and diastolic dystrophy. Hexarelin also decreased the upregulation of TGF-beta expression and secretion caused by angiotensin II.

Atherosclerosis is caused by increased levels of triglycerides and cholesterol. Sprauge-Dawley rats experiencing atherosclerosis were treated with hexarelin. Results found that the formation of atherosclerotic plaques was prohibited. Additionally, hexarelin treatment was seen to lower the ratio of HDLP cholesterol to LDL cholesterol and increase levels of nitric oxide and the mRNA expression of endothelial nitric oxide synthase. While there was little to no change in the triglyceride levels, plasma cholesterol was reduced. This led researchers to conclude that hexarelin is capable of treating atherosclerosis through the regulation of various cholesterol levels (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178518/).

Peptides Prefer the Cold

To reduce peptide breakdown, keep peptides refrigerated at all times but DO NOT FREEZE.
Swab the top of the vial with a 95% alcohol wipe before accessing.
Only Mix with Sterile Bacteriostatic Water
Bacteriostatic water is vital to preventing contamination and preserving the stability of the compound.
Push the needle through the stopper at an angle to direct the stream to the side of the vial.
Reconstituted peptide solution should be stored around 4 degrees Celsius but not frozen, while lyophilized peptide solution should be kept at -20 degrees Celsius.

Hexarelin is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

File Name	View/Download
05-12-2023-Umbrella-Labs-Hexarelin-Certificate-Of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)

 

 

Additional information

Weight	1 oz
Dimensions	0.5 × 0.5 × 1 in